Edmonton Symptom Assessment System (ESAS)
Also known as: ESAS, Edmonton Symptom Assessment Scale
The Edmonton Symptom Assessment System is a rapid, validated 9-item tool that assesses the severity of common symptoms in cancer and palliative care patients: pain, tiredness, nausea, depression, anxiety, drowsiness, appetite loss, general well-being, and shortness of breath. Developed by Bruera and colleagues at the University of Alberta in 1991, the ESAS has become the standard symptom-screening instrument in oncology clinics, palliative care units, and end-of-life care settings worldwide, enabling efficient symptom prioritization and management escalation.
Key highlights
- Ultra-brief and practical (2–3 min, 9 items); feasible for repeated assessment in busy clinic settings and at home. No respondent burden from questionnaire itself.
- Multisymptom coverage; captures prevalent cancer symptoms (pain, fatigue, nausea, mood, dyspnea) not limited to single domains. Enables comprehensive symptom burden assessment.
- Easy-to-understand 0–10 NRS format familiar to cancer patients. Clear Edmonton Zone thresholds (0–3, 4–6, 7–10) for rapid clinical triage and intervention prioritization.
- Extensively validated across cancer types, treatment phases, languages (25+ translations); robust psychometric properties for individual items; responsive to change with symptom-modifying treatments.
- Free for research and clinical use. Widely integrated into cancer center EMR systems and palliative care protocols globally.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
ESAS is appropriate for all cancer patients and treatment contexts: routine oncology clinic screening to identify symptomatic patients and guide supportive care referrals; active treatment (chemotherapy, radiation, surgery) to monitor acute side effects and toxicity; survivorship follow-up to assess long-term symptom burden; palliative care and end-of-life settings for symptom severity assessment and care planning. Use in clinical trials as a secondary outcome to assess tolerability and supportive care efficacy of new therapies. Employ in observational research examining symptom prevalence, risk factors, and trajectories across cancer types and populations. Integrate into cancer center electronic health records for continuous symptom monitoring and automated clinical alerts (e.g., alert if pain ≥7/10).
Strengths & limitations
- Ultra-brief and practical (2–3 min, 9 items); feasible for repeated assessment in busy clinic settings and at home. No respondent burden from questionnaire itself.
- Multisymptom coverage; captures prevalent cancer symptoms (pain, fatigue, nausea, mood, dyspnea) not limited to single domains. Enables comprehensive symptom burden assessment.
- Easy-to-understand 0–10 NRS format familiar to cancer patients. Clear Edmonton Zone thresholds (0–3, 4–6, 7–10) for rapid clinical triage and intervention prioritization.
- Extensively validated across cancer types, treatment phases, languages (25+ translations); robust psychometric properties for individual items; responsive to change with symptom-modifying treatments.
- Free for research and clinical use. Widely integrated into cancer center EMR systems and palliative care protocols globally.
- No composite total score or subscales; individual symptom interpretation requires clinician judgment. No single 'ESAS score' for simplification in research databases.
- Nine items capture common symptoms but may miss patient-specific concerns not listed (e.g., constipation, sleep disturbance, financial distress). Optional 10th open-response item helps but is not standardized.
- Individual items are brief (one-word symptom name); clinical context and follow-up questioning may be needed to clarify fatigue etiology, depression screening, or anxiety specificity.
- NRS format dependent on patient literacy and cognitive ability; requires verbal administration or adaptive response methods (e.g., visual scale) for some populations.
- Lacks scoring complexity; does not assess symptom duration, trajectory, or attributable cause. Requires clinical judgment and longitudinal context for meaningful interpretation.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
What is the difference between ESAS and other symptom-assessment tools?
ESAS (9 symptoms, rapid, 0–10 NRS) is designed for multisymptom screening in busy clinical settings. The Memorial Symptom Assessment Scale (MSAS, 32 items) offers more detailed symptom characterization and distress ratings but requires 10–15 min. The M.D. Anderson Symptom Inventory (MDASI, 19 items) includes symptoms and interference. Choose ESAS for rapid clinical screening and repeated assessment; use MSAS or MDASI if detailed symptom profiling and functional interference are needed.
Can ESAS be used in non-cancer palliative populations?
Yes. ESAS was developed in palliative care and is disease-agnostic. It is widely used in advanced heart failure, COPD, renal failure, and other end-of-life conditions. Symptom prevalence and severity baselines vary by underlying disease; use disease-specific reference data when available. ESAS is particularly valuable for multisymptom, non-cancer chronic illness populations.
How often should ESAS be administered?
Frequency depends on clinical context: routine oncology clinic, baseline and pre-visit (typically weekly to monthly); active treatment (chemotherapy/radiation), weekly or twice-weekly; inpatient palliative care, daily or twice-daily; survivorship, periodically (e.g., every 6–12 months) to monitor persistent symptoms. No universal guideline exists; clinical judgment and setting-specific protocols should guide frequency.
What should I do if a patient reports severe symptoms (≥7/10) on ESAS?
Treat as urgent. Initiate clinical assessment and intervention: pain ≥7 → evaluate pain etiology, adjust analgesia, consider opioid escalation; fatigue ≥7 → assess for depression, anemia, metabolic disorder, optimize nutrition/exercise; anxiety/depression ≥7 → refer to psychology/psychiatry, consider medication or therapy. Do not delay; severe symptoms significantly impair function and QoL. Use ESAS as a trigger for action, not just documentation.
Sources
- 1.Bruera, E., Kuehn, N., Miller, M. J., Selmser, P., & Macmillan, K. (1991). The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care, 7(2), 6–9.
- 2.Chang, V. T., Hwang, S. S., & Kasimis, B. (2000). Longitudinal documentation of cancer pain: a pilot chronic disease management model. Cancer, 88(12), 2892–2900.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). ESAS. ScholarGate. https://scholargate.app/oncology-nursing/edmonton-symptom-assessment